Home » Articles posted by DR ANTHONY MELVIN CRASTO Ph.D (Page 414)
Author Archives: DR ANTHONY MELVIN CRASTO Ph.D
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Hutchison Chi-Med in Partner Talks for Cancer Drug
WO-2011060746 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
may give you the structure
May 9, 2013
Hutchison Chi-Med expects to license global rights to fruqintinib, one of its novel small-cell cancer drugs, before year-end, according to CEO Christian Hogg.
The company has been in due diligence discussions with potential partners, he added. Because the drug is a promising treatment for solid tumors,
Chi-Med will conduct simultaneous clinical trials against several types of cancer, and the company wants a partner to help shoulder the financial burden
Hutchison China MediTech Ltd. (HCM), the drugmaker controlled by Hong Kong billionaire Li Ka-shing, is in talks to license a cancer treatment based on traditional Chinese medicines, Chief Executive Officer Christian Hogg said.
The Hong Kong-based company, known as Chi-Med, completed due diligence with potential partners and will probably reach an agreement on fruquintinib by year-end, Hogg said yesterday in an interview in London, where the shares trade. The medicine may be used to treat colorectal, lung, breast and gastric cancers, he said.
“A deal on fruquintinib is a pretty important priority,” Hogg said. “What we want to do is partner and take on in parallel clinical programs in all of those tumor types.”
A licensing agreement on fruquintinib, which has completed early-stage testing, would follow a joint venture with Nestle SA (NESN), which last month said it has started late-stage trials of HMPL-004 for ulcerative colitis. Chi-Med is aiming to be the first drugmaker to bring to market pharmaceutical products from traditional Chinese botanicals.
Fruquintinib will probably be the last product for which Chi-Med will grant global marketing rights to a partner, with subsequent agreements giving Chi-Med the rights to China, Hogg said. China’s pharmaceutical market is expected to grow as much as 18 percent a year to $165 billion by 2016, making it the world’s second-largest market after the U.S., according to consultancy IMS Health Inc.
PTC Therapeutics’ large-scale multinational trial of ataluren for nonsense-mutation Duchenne or Becker MD has opened its first site in Cincinnati, Ohio
ATALUREN
A large-scale, multinational, phase 3 trial of the experimental drug ataluren has opened its first trial site, in Cincinnati, Ohio.
The trial is recruiting boys with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) caused by anonsense mutation — also known as a premature stop codon — in the dystrophin gene. This type of mutation causes cells to stop synthesizing a protein before the process is complete, resulting in a short, nonfunctional protein. Nonsense mutations are believed to cause DMD or BMD in approximately 10 to 15 percent of boys with these disorders.
Ataluren — sometimes referred to as a stop codon read-through drug — has the potential to overcome the effects of a nonsense mutation and allow functional dystrophin — the muscle protein that’s missing in Duchenne MD and deficient in Becker MD — to be produced.
The orally delivered drug is being developed by PTC Therapeutics, a South Plainfield, N.J., biotechnology company, to whichMDA gave a $1.5 million grant in 2005.
Ataluren, formerly known as PTC124, is a novel small-molecular agent designed to makeribosomes become less sensitive to, or possibly ignore premature stop codons. This may be particularly beneficial in genetic disorders where the mRNA contains a mutation causing premature stop codon or nonsense codon. However, it is not equally effective with every stop codon, working best on the sequence ‘UGA’.
PTC124 has been tested on healthy humans and humans carrying genetic disorderscaused by nonsense mutations,such as some people with cystic fibrosis andDuchenne muscular dystrophy. Clinical trials are proceeding for several genetic disorders, in the subset of affected people who have nonsense mutations (typically <10% of those with the disorder). PTC Therapeutics released preliminary results of its phase 2b clinical trial for Duchenne muscular dystrophy, with participants not showing a significant improvement in the six minute walk distance after the 48 weeks of the trial.However, phase 2 clinical trials were successful for cystic fibrosis in Israel, France and Belgium.Multicountry phase 3 clinical trials are currently in progress for cystic fibrosis in Europe and the USA.
PTC124 has been developed by PTC Therapeutics.
SILDENAFIL, VIAGRA REVIEW
Sildenafil by Anthony Crasto
by ANTHONY MELVIN CRASTO Ph.D on May 11, 2013
- FRESHLY LOADED ON SLIDESHARE
Sildenafil by DR ANTHONY CRASTO, WORLDDRUGTRACKER
CLICK LINK
http://www.slideshare.net/anthonycrasto64/sildenafil-by-anthony-crasto
http://www.slideshare.net/anthonycrasto64/sildenafil-by-anthony-crasto
http://www.slideshare.net/anthonycrasto64/sildenafil-by-anthony-crasto
http://www.slideshare.net/anthonycrasto64/sildenafil-by-anthony-crasto
COLCHININE
Anthony crasto colchinine
by ANTHONY MELVIN CRASTO Ph.D on Apr 06, 2012
- 468 views
Anthony crasto presents colchinine review
http://www.slideshare.net/anthonycrasto64/anthony-crasto-colchinine
http://www.slideshare.net/anthonycrasto64/anthony-crasto-colchinine
http://www.slideshare.net/anthonycrasto64/anthony-crasto-colchinine
http://www.slideshare.net/anthonycrasto64/anthony-crasto-colchinine
Drug Design:Discovery, Development and Delivery
Drug Design:Discovery, Development and Delivery
by Dr. Basavaraj Nanjwade
http://www.slideshare.net/bknanjwade/drug-designdiscovery-development-and-delivery
http://www.slideshare.net/bknanjwade/drug-designdiscovery-development-and-delivery
http://www.slideshare.net/bknanjwade/drug-designdiscovery-development-and-delivery
HERBAL AND DRUG DESIGN TECHNOLOGY
- 9,572 views
an introduction to drug discovery ON SLIDESHARE
http://www.slideshare.net/bishorvi/introduction-to-drug-discovery
http://www.slideshare.net/bishorvi/introduction-to-drug-discovery
http://www.slideshare.net/bishorvi/introduction-to-drug-discovery
Amgen sets up China JV with Zhejiang Beta for Panitumumab,Vectibix
Amgen is expanding its activities in China and establishing a joint venture with Zhejiang Beta Pharma Co to sell its colon cancer drug Vectibix, Panitumumab.
http://www.pharmatimes.com/Article/13-05-10/Amgen_sets_up_China_JV_with_Zhejiang_Beta.aspx
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.
It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for “the treatment of EGFR-expressing metastatic colorectal cancer with disease progression” despite prior treatment. Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for “the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS”.
Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations.
FDA Approves Breo Ellipta to Treat Chronic Obstructive Pulmonary Disease (COPD)
fluticasone furoate
vilanterol
May 10, 2013 — The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations.
COPD is a serious lung disease that worsens over time. Symptoms can include chest tightness, chronic cough and excessive phlegm. Cigarette smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute, and COPD is the third leading cause of death in the United States.
Breo Ellipta works by decreasing inflammation in the lungs and helping the muscles around the airways of the lungs stay relaxed to increase airflow and reduce exacerbations in patients with COPD.
The challenges facing the pharmaceutical industry through to 2020
The challenges facing the pharmaceutical industry through to 2020
link on slideshare is
by Irish Pharmaceutical Healthcare Association (IPHA) on Nov 12, 2009
- 22,073 views on slideshare
Presentation delivered by Mr Sandy Johnston, PriceWaterhouseCoopers at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
US green light for Warner Chilcott’s new contraceptive
May 10, 2013
US regulators have issued a green light for Warner Chilcott’s new oestrogen/progestin-based oral contraceptive, which is yet to be given an official trade name.
The product is a chewable combination of norethindrone acetate and ethinyl estradiol and ferrous fumarate tablets, approved by the US Food and Drug Administration for the prevention of pregnancy.
The oral contraceptive regimen consists of 24 white active chewable tablets that contain the active ingredients, followed by four brown non-hormonal placebo tablets containing ferrous fumarate.
Approval was based on data from a six-month clinical trial involving 743 women aged 18-45 years, which showed the risk of getting pregnant to be about one-four in 100 women during the first year of use.
New Drug Approvals 